cbdMD Engages Leading Biotech Firm IONTOX to Validate Its Patent Pending Superior Broad Spectrum Blend

Validation Creates Pathway For New Water-Soluble Formulation For Beverages

CHARLOTTE, N.C.–(BUSINESS WIRE)–cbdMD, Inc. (NYSE American: YCBD, YCBD.PR.A), one of the nation’s leading and most highly trusted and recognized cannabidiol (CBD) brands, announced today that it has retained nationally recognized biotechnology company IONTOX (https://www.iontox.com), to validate the Company’s patent pending proprietary cannabinoid formulations. On July 9, 2020, cbdMD announced it had filed provisional patents on its novel formulations and delivery systems. This is the next step in demonstrating the safety and efficacy of those formulations, including a new water-soluble formulation for beverages.

“IONTOX has extensive expertise in in vitro technology which utilizes novel techniques and testing methods for the safety of botanical dietary ingredients. These analyses will provide valuable insight to both current and future product formulation for cbdMD and we are honored that such a respected company would select IONTOX for this important research,” said Jim McKim, President of IONTOX.

“As part of our ongoing science based approach, we are staying ahead of current safety and testing methods by seeking to validate our patent pending proprietary cannabinoid blends and delivery systems. In addition to seeking FSA approval in the United Kingdom and our preparations for an eventual NDIN submission to the FDA, we are committed to the underlying science as demonstrated by our partnership with IONTOX, who have worked with some of the biggest names in research, such as: Dow, Unilever, Amway, Pfizer, Biogen and L’Oréal Paris. Working with IONTOX not only helps cbdMD’s regulatory submissions, but also demonstrates our commitment to leading with science. We continue our commitment as a leader in the development of innovative novel CBD products,” said Chairman & Co-CEO, Martin A. Sumichrast. (Read more…)

About IONTOX

IONTOX is a biotechnology company founded in 2014 dedicated to providing expertise to the area of in vitro toxicology, with a mission to build improved methods for predicting human adverse effects from chemical exposure. From laboratories located in Kalamazoo, Michigan, IONTOX serves a global client base in the pharmaceutical, cosmetic, chemical, tobacco, and food additive industries. Through, consulting, product development, and laboratory services the company contributes to the development, application, and interpretation of alternative testing methods. IONTOX aims to advance current alternative toxicology methods through continuous efforts in the research and development of new in vitro technology. Through the company’s contract research laboratories IONTOX offers Advanced in vitro solutions that promise to increase the reliability of in vitro toxicology.

About cbdMD, Inc.

cbdMD, Inc. is one of the leading, most highly trusted, and most recognized cannabidiol (CBD) brands, whose current products include CBD tinctures, CBD capsules, CBD gummies, CBD topicals, CBD bath bombs and CBD pet products. cbdMD is also a proud partner of Bellator MMA and Life Time, Inc., and has one of the largest rosters of professional sports athletes who are part of “Team cbdMD.” To learn more about cbdMD and our comprehensive line of over 100 SKUs of U.S. produced, Non-THC¹ CBD products, please visit www.cbdMD.com, follow cbdMD on Instagram and Facebook, or visit one of the 6,000 retail outlets that carry cbdMD products.

¹ Non-THC is defined as below the level of detection using validated scientific analytical tools.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and Part II, Item 1A. Risk Factors appearing in its Quarterly Report on Form 10-Q for the period ended June 30, 2020, both as filed with the Securities and Exchange Commission (the “SEC”) and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

Contacts

PR:

cbdMD, Inc.

Lauren Greene

Communications Specialist

[email protected]
(843) 743-9999

Investors:

cbdMD, Inc.

John Weston

Director of Investor Relations

[email protected]
(704) 249-9515